JOURNAL HOME CME HOME THIS MONTH PAST ISSUES ETOC COLLECTIONS
AUTHORS REVIEWERS EDITORIAL BOARD FEEDBACK RSS HELP
A&A International Anesthesia Research Society
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (7)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Liguori, G. A.
Right arrow Articles by Figgie, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Liguori, G. A.
Right arrow Articles by Figgie, M.
Related Collections
Right arrow Regional Anesthesia
Right arrow Pharmacology
Anesth Analg 2002;94:1010-1013
© 2002 International Anesthesia Research Society


REGIONAL ANESTHESIA

Possible Bupivacaine Toxicity After Intraarticular Injection for Postarthroscopic Analgesia of the Knee: Implications of the Surgical Procedure

Gregory A. Liguori, MD*, George F. Chimento, MD{dagger}, Leslie Borow, MD*, and Mark Figgie, MD{dagger}

Departments of *Anesthesiology and {dagger}Orthopedic Surgery, Hospital for Special Surgery, Weill Medical College of Cornell University, New York, New York

Address correspondence and reprint requests to Gregory A. Liguori, MD, Department of Anesthesia, Hospital for Special Surgery, 535 East 70th Street, New York, New York, 10021.


    Abstract
 Top
 Abstract
 Introduction
 Case Report
 Discussion
 References
 

IMPLICATIONS: We report a case of possible bupivacaine toxicity after intraarticular injection during knee arthroscopy. The importance of the specific type of surgical procedure performed during arthroscopy and its relationship to potential local anesthetic toxicity are highlighted.


    Introduction
 Top
 Abstract
 Introduction
 Case Report
 Discussion
 References
 
Arthroscopic surgical procedures of the knee joint have increased in popularity over the past decade. As technologies progress, orthopedic surgeons are able to perform more complex procedures using arthroscopic equipment. Anesthetic techniques used for knee arthroscopy have included general, spinal, epidural, regional nerve block, and local anesthesia with and without sedation. Although many arthroscopic procedures are not associated with severe postoperative pain, providing patients with adequate analgesia may affect the recovery profile (1). Multimodal analgesic regimes are commonly used after arthroscopy of the knee. One important mode of analgesia is achieved by intraarticular injection of a variety of analgesics, most commonly local anesthetics, at the conclusion of the arthroscopic procedure. A widely used local anesthetic for intraarticular injection is bupivacaine. Its prolonged duration of action makes it well suited for postoperative analgesia in this surgical population. Complications associated with the injection of intraarticular bupivacaine have rarely appeared in the literature. We present a case of possible local anesthetic toxicity secondary to intraarticular bupivacaine administration after arthroscopic surgery of the knee.


    Case Report
 Top
 Abstract
 Introduction
 Case Report
 Discussion
 References
 
The patient was a 44-yr-old, 97-kg, 163-cm male with a history of a moderately severe blow to the anterior aspect of an extended left knee incurred while playing basketball several months earlier. The injury was manifested by knee pain with stair climbing, occasional swelling, and a buckling sensation. He had no significant past medical or surgical history. Preoperative evaluation revealed a blood pressure of 110/70 mm Hg, pulse of 68 bpm, and a respiratory rate of 20 breaths/min. Physical examination of the heart and lungs was unremarkable. Examination and imaging studies of the knee were consistent with intraarticular loose bodies, an increased patellar tilt, and a cartilage defect of the femoral sulcus. Laboratory examination was remarkable for a hematocrit of 40.3 and prothrombin and partial thromboplastin times that were within normal limits. His electrocardiogram (ECG) revealed normal sinus rhythm of 66 bpm, normal axis and intervals, no ST-T wave abnormalities, and no suggestion of {delta} waves.

Upon arrival in the operating room, a noninvasive blood pressure cuff, three-lead ECG, and pulse oximeter were applied. Midazolam (Versed, Roche, Manati PR) 5 mg IV in divided doses was given over several minutes. An uneventful spinal anesthetic (3 mL of 1.5% mepivacaine (Polocaine, Astra, Westborough, MA)) was administered. During the course of the procedure, the patient received an additional 2 mg of midazolam and 60 mg of propofol (Diprivan, Zeneca, Wilmington, DE), and was awake and drowsy for most of the operation. Blood pressure and heart rate varied <10% from baseline, and SpO2 was 100% throughout the procedure.

The patient underwent a knee arthroscopy in the supine position. Neither a leg holder nor tourniquet was used. Arthroscopic irrigation consisted of normal saline with 0.33 µg/mL of epinephrine at variable flow rates. Superolateral, anteromedial, and anterolateral portals were used. After diagnostic arthroscopy, several small loose bodies were removed from the posteromedial aspect of the joint. Subsequent to this, a lateral retinacular release was performed using an arthroscopic electrocautery device. Attention was then turned to the femoral sulcus, where a 2 cm x 3 cm full-thickness cartilage defect was identified. A microfracture technique was used in an effort to treat this. Several (5–10) small holes were made into the subchondral plate in the area of the defect with awls designed for such a purpose. The entire arthroscopic time was less than 1 h.

On completion of the procedure, bupivacaine 0.25% (Sensorcaine, Astra, Westborough, MA) 20 mL with 40 mg of methylprednisolone (Depomedrol, Pharmacia Upjohn, Kalamazoo, MI) was injected percutaneously into the knee joint in a single bolus via a 20-gauge needle. Epinephrine was not included in the injectate. Within 1–2 min, the patient complained of chest heaviness, nausea, and lightheadedness. He was noted to be pale and diaphoretic. He did not exhibit seizure activity and did not lose consciousness. Simultaneously, his ECG revealed a junctional, wide complex tachycardia at 110 bpm. Blood pressure was 100/60 mm Hg and SpO2 was 99%. Metoprolol (Abbott Laboratories, North Chicago, IL) 5 mg IV was administered. The heart rate slowed and converted to normal sinus rhythm. The QRS complex remained prolonged and T-wave inversions were noted on the monitor.

At arrival in the postanesthesia care unit, the patient remained hemodynamically stable, with slow resolution of his symptoms. A 12-lead ECG revealed T-wave inversions in leads III and aVF with a normal QRS complex. The T- waves reverted to normal over the next several hours. The patient was discharged home later that day and had an uneventful postoperative course.


    Discussion
 Top
 Abstract
 Introduction
 Case Report
 Discussion
 References
 
Adequate analgesia after knee arthroscopy not only adds to patient’s acceptance of this procedure on an outpatient basis, but may also affect the recovery profile and discharge times from the hospital (1). Bupivacaine is an ideal drug to achieve postarthroscopic analgesia of the knee (14). Since those reports, bupivacaine has been used in combination with, or as a control for, a variety of other intraarticular analgesics such as ketorolac (5,6), morphine (711), and clonidine (12). Conversely, several studies have failed to show a benefit to intraarticular instillation of bupivacaine (1315). Despite these latter reports, the use of bupivacaine as part of postarthroscopic analgesic regimes is widely accepted.

When noted, the arthroscopic procedures performed in the aforementioned investigations included medial and lateral meniscectomies, meniscal repairs, diagnostic arthroscopies, and removal of loose bodies. No complications of local anesthetic toxicity were described in any of these reports. However, it is important to consider the tissue upon which the arthroscopic procedure is being performed. The meniscus is a very avascular structure; hence its inability to heal when traumatized. Loose bodies are avascular. During operations on these tissues, there is little opportunity for entry of local anesthetics into vascular beds.

Sullivan and Abbott (16) published two cases of bupivacaine toxicity after intraarticular injection. The first case involved a preoperative injection of 60 mL 0.25% bupivacaine with epinephrine. The signs and symptoms experienced by that patient were similar to our case. In addition, the dysrhythmia reported, "a wide QRS with inverted T waves.... with tachycardia" was identical to the rhythm observed in our patient.

The second case also involved a preoperative injection of 30 mL 0.25% bupivacaine with epinephrine. Intraoperatively, a fracture of the lateral femoral condyle was noted. The authors speculate that this fracture provided access to the systemic circulation.

Several studies have evaluated blood levels of bupivacaine after intraarticular injection after knee arthroscopy (4,17). Meinig et al. (17) measured venous samples of plasma bupivacaine levels after intraarticular instillation of 30 mL of 0.5% bupivacaine and found mean plasma levels to be <650 ng/mL with a peak level occurring at 20 min after injection. Kaeding et al. (4) reported peak bupivacaine levels of 480 ng/mL occurring at 43 min after instillation. These levels are 8 to 10 times less than those reported to cause convulsions in humans (18). It is very unlikely that without a direct intravascular route, toxicity from intraarticular instillation of local anesthetic can occur. The arthroscopic procedures performed during these studies included meniscectomies, meniscal repairs, abrasion chondroplasty, plicectomy, and debridement. Again, these procedures involve surgical manipulation of relatively avascular structures within the knee joint.

The microfracture technique used for this patient has been previously described as a treatment for full-thickness cartilage injuries of the knee (19). Awls are used to create holes in the subchondral bone plate in the area of the cartilage defect. The overall integrity of the subchondral bone is maintained. The holes allow for the intraarticular release of marrow elements, which presumably enhance tissue regeneration. The holes, however, also allow intraarticular fluids to pass into the marrow cavity, and subsequently, into the systemic circulation. We postulate this to be the mechanism for the proposed intravascular uptake of local anesthetic. In addition, the performance of a lateral release traumatizes highly vascularized tissues and exposes the vasculature to intraarticular fluids. This mechanism is similar to that described by Sullivan and Abbott (16), except that the "chondral fracture" they reported was made intentionally in this case. We believe that a reaction such as this has never been reported despite the use of intraarticular local anesthetic in hundreds of patients in the previously referenced studies. As noted, these studies did not involve the microfracture technique or lateral release during arthroscopy.

The reaction experienced by our patient occurred one to two minutes after the local anesthetic injection. A toxic reaction caused by an increased blood level of local anesthetic taken up by a normal knee joint would not normally occur so quickly (4,17). Therefore, this episode may be similar to an intravascular injection of local anesthetic. Furthermore, the fact that the reaction occurred within 1 to 2 minutes of injection gives further support to the hypothesis that inadvertent intravascular uptake of the local anesthetic is the most likely etiology.

Other explanations for this reaction may include a coincidental wide complex tachycardia on the basis of preexistent cardiac pathology. Examples of underlying cardiac pathology that would present as a wide complex tachycardia include long QT syndrome and Wolff-Parkinson-White (WPW) syndrome (20). The long QT syndrome can either be acquired or congenital. Acquired forms are caused by several classes of antiarrhythmics, phenothiazines, tricyclic antidepressants, IV erythromycin, and organophosphate insecticides. In addition, altered nutritional states and electrolyte abnormalities may precipitate long QT syndrome-induced tachyarrhythmias.

Congenital forms are associated with enhanced adrenergic responsiveness. These patients often present with syncope during childhood in the setting of heightened sympathetic tone.

WPW syndrome is associated with young healthy patients experiencing episodes of tachycardia because of multiple atrioventricular (AV) connections. ECG characteristics include a short PR interval and a broad QRS complex with an abnormal initial deflection. The tachycardia is initiated by a properly timed atrial or ventricular premature beat that is blocked in one of the two AV connections.

Although these or other preexistent syndromes may be responsible for those experienced by our patient, there is no evidence to support this conclusion. The patient has previously been, and continues to be asymptomatic, and without invasive electrophysiologic testing these syndromes can neither be implicated nor eliminated.

Epinephrine was used in very dilute concentrations in the irrigating solution only; it was not used in the injectate. If this dysrhythmia was an exogenous catecholamine reaction from the epinephrine in the irrigating solution, one would expect the reaction to occur during the course of the arthroscopic procedure while the solution is pressurized in the knee joint. Therefore, an exogenous catecholamine reaction causing these symptoms could likely be excluded.

This event was not a prototypical local anesthetic reaction characterized by central nervous system toxicity and progressing to cardiovascular collapse. The patient did not have an overt seizure despite experiencing lightheadedness, pallor, and diaphoresis. The use of benzodiazepines as sedation may have altered the seizure threshold, thereby masking a clinically apparent seizure. The patient’s symptoms were more consistent with a vasovagal type reaction that has been reported after spinal (21) or epidural (22) anesthesia. The most common dysrhythmia associated with spinal anesthesia is bradycardia. Risk factors for the development of bradycardia during spinal anesthesia include a baseline heart rate <60 bpm, ASA physical status I, ß blocker usage, sensory level above T6, age <50 years, and prolonged PR interval (23). The mechanism is thought to be related in part to heightened vagal tone. However, the wide complex tachycardia is not consistent with increased vagal activity and therefore supports local anesthetic toxicity as the mechanism of this event.

Brown (24) describes three cardiovascular phases during a systemic toxic reaction to local anesthetics. First, an excitatory phase associated with sympathetic discharge and tachycardia occurs. This may be a response to central nervous system toxicity. The second phase is characterized by myocardial depression and decreased cardiac output. The final phase is associated with conduction abnormalities and cardiovascular collapse. The reaction experienced by our patient was most consistent with the sympathetic discharge phase (25) and responded to IV beta blockade. However, we believe that the widening of the QRS complex and T-wave inversions were reflective of bupivacaine’s effects on the conduction system.

The use of ß blockers is not the standard treatment for local anesthetic-induced conduction abnormalities. Although ß blockers may be useful in treating the excitatory cardiovascular phase, the potential to progress to the second and third phases with myocardial depression and collapse precludes their routine use. The treatment for local anesthetic-induced cardiac toxicity is generally supportive, and may include amrinone, closed chest cardiac massage, and cardiopulmonary bypass. In addition, effective ventilation with oxygen is essential (26). In this case, the relationship between the cardiovascular symptoms and the injection of bupivacaine was not immediately recognized. Therefore metoprolol was used to treat the tachycardia. In retrospect, metoprolol was effective in this case; however, the routine use of ß blockers as a treatment for local anesthetic toxicity is not advocated.

In conclusion, we have reported a case of presumed local anesthetic toxicity after intraarticular injection of 0.25% bupivacaine after arthroscopic knee surgery using a microfracture technique for repair of a cartilage defect, as well as an arthroscopic lateral release. Anesthesiologists and orthopedic surgeons should bear in mind the surgical procedure performed during knee arthroscopy and the potential for intravascular uptake of local anesthetic. When the meniscus, loose bodies, or other relatively avascular structures are being manipulated, there seems to be a body of evidence supporting the safe instillation of intraarticular bupivacaine. However, procedures such as the microfracture technique and lateral release involve invasion into more vascular structures within the knee joint. Intraarticular instillation of bupivacaine in these patients may carry an increased risk of intravascular injection of local anesthetic. Clinicians should carefully consider the risks and benefits of this practice in this surgical population.


    Acknowledgments
 
The authors would like to extend their appreciation to Thomas J. J. Blanck, MD, PhD for reviewing this report, and to George Go for technical assistance and editing.


    References
 Top
 Abstract
 Introduction
 Case Report
 Discussion
 References
 

  1. Smith I, Van Hemelrijck J, White PF, Shively R. Effects of local anesthesia on recovery after outpatient arthroscopy. Anesth Analg 1991; 73: 536–9.[Abstract/Free Full Text]
  2. Nole R, Munson NM, Fulkerson JP. Bupivacaine and saline effects on articular cartilage. Arthroscopy 1985; 1: 123–7.[Medline]
  3. Chirwa SS, MacLeod BA, Day B. Intraarticular bupivacaine (Marcaine) after arthroscopic meniscectomy: a randomized double-blind controlled study. Arthroscopy 1989; 5: 33–5.[Medline]
  4. Kaeding CC, Hill JA, Katz J, Benson L. Bupivacaine use after knee arthroscopy: pharmacokinetics and pain control study. Arthroscopy 1990; 6: 33–9.[Medline]
  5. Reuben SS, Connelly NR. Postoperative analgesia for outpatient arthroscopic knee surgery with intraarticular bupivacaine and ketorolac. Anesth Analg 1995; 80: 1154–7.[Abstract]
  6. Reuben SS, Connelly NR. Postarthroscopic meniscus repair analgesia with intraarticular ketorolac or morphine. Anesth Analg 1996; 82: 1036–9.[Abstract]
  7. Allen GC, St Amand MA, Lui AC, et al. Postarthroscopy analgesia with intraarticular bupivacaine/morphine: a randomized clinical trial. Anesthesiology 1993; 79: 475–80.[ISI][Medline]
  8. Heard SO, Edwards WT, Ferrari D, et al. Analgesic effect of intraarticular bupivacaine or morphine after arthroscopic knee surgery: a randomized, prospective, double-blind study. Anesth Analg 1992; 74: 822–6.[Abstract/Free Full Text]
  9. Khoury GF, Chen AC, Garland DE, Stein C. Intraarticular morphine, bupivacaine, and morphine/bupivacaine for pain control after knee videoarthroscopy. Anesthesiology 1992; 77: 263–6.[ISI][Medline]
  10. Raja SN, Dickstein RE, Johnson CA. Comparison of postoperative analgesic effects of intraarticular bupivacaine and morphine following arthroscopic knee surgery. Anesthesiology 1992; 77: 1143–7.[ISI][Medline]
  11. Ruwe PA, Klein I, Shields CL. The effect of intraarticular injection of morphine and bupivacaine on postarthroscopic pain control. Am J Sports Med 1995; 23: 59–64.[Abstract/Free Full Text]
  12. Reuben SS, Connelly NR. Postoperative analgesia for outpatient arthroscopic knee surgery with intraarticular clonidine. Anesth Analg 1999; 88: 729–33.[Abstract/Free Full Text]
  13. Aasbo V, Raeder JC, Grogaard B, Roise O. No additional analgesic effect of intra-articular morphine or bupivacaine compared with placebo after elective knee arthroscopy. Acta Anaesthesiol Scand 1996; 40: 585–8.[ISI][Medline]
  14. Henderson RC, Campion ER, DeMasi RA, Taft TN. Postarthroscopy analgesia with bupivacaine: a prospective, randomized, blinded evaluation. Am J Sports Med 1990; 18: 614–7.[Abstract/Free Full Text]
  15. Joshi GP, McCarroll SM, O’Brien TM, Lenane P. Intraarticular analgesia following knee arthroscopy. Anesth Analg 1993; 76: 333–6.[ISI][Medline]
  16. Sullivan SG, Abbott PJ Jr . Cardiovascular toxicity associated with intraarticular bupivacaine. Anesth Analg 1994; 79: 591–3.[Free Full Text]
  17. Meinig RP, Holtgrewe JL, Wiedel JD, et al. Plasma bupivacaine levels following single dose intraarticular instillation for arthroscopy. Am J Sports Med 1988; 16: 295–300.[Abstract/Free Full Text]
  18. Moore DC, Balfour RI, Fitzgibbons D. Convulsive arterial plasma levels of bupivacaine and the response to diazepam therapy. Anesthesiology 1979; 50: 454–6.[ISI][Medline]
  19. Steadman JR, Rodkey WG, Briggs KK, Rodrigo JJ. The microfracture technic in the management of complete cartilage defects in the knee joint [in German]. Orthopade 1999; 28: 26–32.[ISI][Medline]
  20. Janse MJ. Reentrant arrhythmias. In: Fozzard HA, Haber E, Jennings RB, et al., eds. The heart and cardiovascular system. New York: Raven Press, 1991: 2077–106.
  21. Mackey DC, Carpenter RL, Thompson GE, et al. Bradycardia and asystole during spinal anesthesia: a report of three cases without morbidity. Anesthesiology 1989; 70: 866–8.[ISI][Medline]
  22. Liguori GA, Sharrock NE. Asystole and severe bradycardia during epidural anesthesia in orthopedic patients. Anesthesiology 1997; 86: 250–7.[ISI][Medline]
  23. Pollard JB. Cardiac arrest during spinal anesthesia: common mechanisms and strategies for prevention. Anesth Analg 2001; 92: 252–6.[Free Full Text]
  24. Brown DL. Local anesthetic toxicity. In: Finucane BT, ed. Complications of regional anesthesia. Philadelphia: Churchill-Livingstone, 1999: 94–104.
  25. Brown DL, Ransom DM, Hall JA, et al. Regional anesthesia and local anesthetic-induced systemic toxicity: seizure frequency and accompanying cardiovascular changes. Anesth Analg 1995; 81: 321–8.[Abstract]
  26. Tetzlaff JE. Cardiac toxicity. In: Clinical pharmacology of local anesthetics. Woburn: Butterworth-Heinemann 2000: 43–4.
Accepted for publication November 16, 2001.




This article has been cited by other articles:


Home page
J Bone Joint Surg BrHome page
C. R. Chu, N. J. Izzo, C. H. Coyle, N. E. Papas, and A. Logar
The in vitro effects of bupivacaine on articular chondrocytes
J Bone Joint Surg Br, June 1, 2008; 90-B(6): 814 - 820.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (7)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Liguori, G. A.
Right arrow Articles by Figgie, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Liguori, G. A.
Right arrow Articles by Figgie, M.
Related Collections
Right arrow Regional Anesthesia
Right arrow Pharmacology


Lippincott, Williams & Wilkins Anesthesia & Analgesia® is published for the International Anesthesia Research Society® by Lippincott Williams & Wilkins with the assistance of Stanford University Libraries' HighWire Press®. Copyright 2006 by the International Anesthesia Research Society. Online ISSN: 1526-7598   Print ISSN: 0003-2999 HighWire Press